IL292363A - Anti-beta-amyloid antibody for the treatment of Alzheimer's disease - Google Patents

Anti-beta-amyloid antibody for the treatment of Alzheimer's disease

Info

Publication number
IL292363A
IL292363A IL292363A IL29236322A IL292363A IL 292363 A IL292363 A IL 292363A IL 292363 A IL292363 A IL 292363A IL 29236322 A IL29236322 A IL 29236322A IL 292363 A IL292363 A IL 292363A
Authority
IL
Israel
Prior art keywords
antibody
subject
seq
tau
amino acid
Prior art date
Application number
IL292363A
Other languages
English (en)
Hebrew (he)
Original Assignee
Biogen Ma Inc
Neurimmune Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Ma Inc, Neurimmune Ag filed Critical Biogen Ma Inc
Publication of IL292363A publication Critical patent/IL292363A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
IL292363A 2019-10-22 2020-10-21 Anti-beta-amyloid antibody for the treatment of Alzheimer's disease IL292363A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962924633P 2019-10-22 2019-10-22
PCT/US2020/056676 WO2021081101A1 (en) 2019-10-22 2020-10-21 Anti-beta-amyloid antibody for treating alzheimer's disease

Publications (1)

Publication Number Publication Date
IL292363A true IL292363A (en) 2022-06-01

Family

ID=73344157

Family Applications (1)

Application Number Title Priority Date Filing Date
IL292363A IL292363A (en) 2019-10-22 2020-10-21 Anti-beta-amyloid antibody for the treatment of Alzheimer's disease

Country Status (13)

Country Link
US (1) US20220372123A1 (cg-RX-API-DMAC10.html)
EP (1) EP4048695A1 (cg-RX-API-DMAC10.html)
JP (2) JP2022553329A (cg-RX-API-DMAC10.html)
KR (1) KR20220084095A (cg-RX-API-DMAC10.html)
CN (1) CN114599393A (cg-RX-API-DMAC10.html)
AU (1) AU2020371612A1 (cg-RX-API-DMAC10.html)
BR (1) BR112022007595A2 (cg-RX-API-DMAC10.html)
CA (1) CA3158513A1 (cg-RX-API-DMAC10.html)
CO (1) CO2022004902A2 (cg-RX-API-DMAC10.html)
IL (1) IL292363A (cg-RX-API-DMAC10.html)
JO (1) JOP20220092A1 (cg-RX-API-DMAC10.html)
MX (1) MX2022004678A (cg-RX-API-DMAC10.html)
WO (1) WO2021081101A1 (cg-RX-API-DMAC10.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
EP3746476A1 (en) 2018-01-31 2020-12-09 Alector LLC Anti-ms4a4a antibodies and methods of use thereof
EP3746484A4 (en) 2018-01-31 2021-11-17 Alector LLC ANTI-MS4A6A ANTIBODY AND METHOD OF USING THEREOF
KR20210124308A (ko) 2019-01-30 2021-10-14 트루바인딩 아이엔씨. 항-gal3 항체 및 이의 용도
MX2022014786A (es) 2020-05-26 2023-01-16 Truebinding Inc Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3.
TW202300517A (zh) * 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗類澱粉β抗體及其用途
TW202300518A (zh) * 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗N3pGlu類澱粉β抗體及其用途
WO2023081194A2 (en) * 2021-11-03 2023-05-11 Biogen Ma Inc. Methods for treating alzheimer's disease
KR20240142535A (ko) * 2022-02-02 2024-09-30 에자이 알앤드디 매니지먼트 가부시키가이샤 P-tau181 수준을 사용한 치료 방법
WO2024086796A1 (en) * 2022-10-20 2024-04-25 Alector Llc Anti-ms4a4a antibodies with amyloid-beta therapies
EP4608432A4 (en) * 2022-10-25 2026-08-12 Inst For Basic Science Ibs EXTRACTION METHODS TO ENABLE CEREBRAL-SPINAL FLUID DRAINAGE
EP4455161A1 (en) 2023-04-24 2024-10-30 ONO Pharmaceutical Co., Ltd. Human-derived anti-collapsin response mediator protein 2 (crmp2) antibodies
WO2025059487A2 (en) 2023-09-15 2025-03-20 Othair Prothena Limited Cell penetrating agents and uses thereof
WO2025117721A1 (en) * 2023-11-27 2025-06-05 Massachusetts Institute Of Technology Reconstituted lipoprotein particles to rescue lipid defects in the alzheimer's brain

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE033325T2 (en) 2007-01-05 2017-11-28 Univ Zuerich Anti-beta-amyloid binder antibodies and their use
US9040045B2 (en) * 2007-05-14 2015-05-26 Medtronic, Inc. Methods and device to neutralize soluble toxic agents in the brain
JO3076B1 (ar) * 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
US9221900B2 (en) * 2010-07-30 2015-12-29 Ac Immune S.A. Methods for identifying safe and functional humanized antibodies
EP3275461A1 (en) * 2011-09-19 2018-01-31 Axon Neuroscience SE Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease field
EP2928494A4 (en) * 2012-12-07 2016-11-02 Biogen Internat Neuroscience Gmbh METHOD FOR REDUCING AMYLOIDER PLAQUE OF BRAIN WITH ANTI-ASS ANTIBODIES
MA41115A (fr) * 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
MX2018015022A (es) * 2016-06-07 2019-08-14 Biogen Int Neuroscience Gmbh Métodos para el tratamiento de la enfermedad de alzheimer.

Also Published As

Publication number Publication date
CO2022004902A2 (es) 2022-07-08
JP2022553329A (ja) 2022-12-22
EP4048695A1 (en) 2022-08-31
CN114599393A (zh) 2022-06-07
BR112022007595A2 (pt) 2022-08-23
US20220372123A1 (en) 2022-11-24
AU2020371612A1 (en) 2022-05-19
CA3158513A1 (en) 2021-04-29
JOP20220092A1 (ar) 2023-01-30
KR20220084095A (ko) 2022-06-21
MX2022004678A (es) 2022-08-15
WO2021081101A1 (en) 2021-04-29
JP2026012271A (ja) 2026-01-23

Similar Documents

Publication Publication Date Title
US20220372123A1 (en) Anti-beta-amyloid antibody for treating alzheimer's disease
US20260091109A1 (en) Method for Treating Alzheimer's Disease
US20220281963A1 (en) Methods for treating alzheimer's disease
KR20250114372A (ko) 타우(tau) pet 수준을 이용하는 치료 방법
JP2025506389A (ja) ｐ－タウ１８１レベルを使用した治療方法
US20250051427A1 (en) Methods of using an anti-amyloid beta protofibril antibody and anti-tau antibody
US20240425573A1 (en) Methods for treating alzheimer's disease
US20240270830A1 (en) Methods for treating alzheimer's disease
TW202513583A (zh) 使用抗Ａβ初原纖維抗體之治療方法
EA052963B1 (ru) Способы применения антитела к протофибриллам бета-амилоида и антитела к тау-белку
NZ788486A (en) Methods for treating Alzheimer's disease